Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

VOLUNTARY ANNOUNCEMENT – JS105 RECEIVED NOTICE OF APPROVAL FOR CLINICAL TRIAL

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 25 May 2022.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, Junshi Risen (Shanghai) Pharmaceutical Technology Co., Ltd.* (君實潤佳(上海)醫藥科技有限公司) ("**Junshi Risen**"), a company jointly invested by the Company and Risen (Suzhou) Pharma Tech Co., Ltd.* (潤佳(蘇州)醫藥科技有限公司) ("**Risen Pharma**") has received the Notice of Approval for Clinical Trial* (《藥物臨床試驗批准通知書》) issued by the National Medical Products Administration. The investigational new drug application for the PI3K-α inhibitor RP903 tablets (project code: "**JS105**") has been approved. Relevant information is as follows:

ABOUT JS105

Drug name: RP903 tablets
Application matter: Clinical Trial of Domestic Production Registration of Pharmaceutical Product
Acceptance No.: CXHL2200179 and CXHL2200180
Applicant: Junshi Risen (Shanghai) Pharmaceutical Technology Co., Ltd.* (君實潤佳(上海)醫藥科技有限公司)
Review conclusion: According to the Drug Administration Law of the People's Republic of China* (《中華人民共和國藥品管理法》) and relevant regulations, upon review, the RP903 tablets accepted on 22 March 2022 meet the relevant requirements for drug registration and are approved to conduct clinical trials on advanced malignant solid tumors in accordance with the proposal submitted.

JS105 is an oral small molecule inhibitor targeting PI3K-α and is primarily used in the treatment of female (post-menopausal) and male patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced breast cancer who are experiencing disease progression during or after treatment with endocrine-based regimens. Pre-clinical studies have shown that JS105 is effective in animal models of breast cancer, and also in other solid tumours such as cervical cancer, kidney cancer, colorectal cancer and oesophageal cancer. JS105 has also demonstrated good safety.

In February 2019, the Company and Risen Pharma entered into the Technology Transfer and Collaboration Agreement, pursuant to which the Company acquired a 50% interest globally in two inhibitor projects, including JS105, from Risen Pharma. In April 2021, the Company entered into a joint investment contract with Risen Pharma to jointly invest in the establishment of Junshi Risen, which shall be responsible for the research and development, clinical application, production and commercialization of JS105 in the joint establishment region. Each of the Company and Risen Pharma owns 50% equity interest in Junshi Risen.

As at the date of this announcement, there is only one PI3K-α inhibitor, Piqray® (Alpelisib, a product of Novartis), approved for the treatment of HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in the world, and no PI3K-α inhibitor has been approved for marketing in the People's Republic of China.

RISK WARNING

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. These many stages make it susceptible to uncertainties and therefore, investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the above research and development project and fulfill its information disclosure obligations in a timely manner for subsequent progress in strict compliance with relevant regulations.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 25 May 2022

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng and Mr. Li Cong as executive Directors; Dr. Wu Hai, Mr. Tang Yi and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Feng Xiaoyuan as independent non-executive Directors.

* *For identification purpose only*